Spinal fluid test doesn't predict long-term MS disability

Credibility

Interest

Key Takeaway

Having extra white blood cells in the spinal fluid at MS diagnosis did not predict worse long-term disability over about 13 years.

What They Found

Doctors looked at 247 people with MS for about 13 years to see if lymphocytic pleocytosis (more white blood cells in the spinal fluid) meant a worse outcome. They measured disability with scores like EDSS and MSSS, which are ways clinicians track how MS affects movement and daily life (EDSS rates disability from 0 to 10; MSSS compares that score to others). About 18% of people had elevated white blood cells in their cerebrospinal fluid, but these people did not have higher disability at the time of the test or later on. The group with extra white blood cells did not show faster yearly worsening or a quicker change to the secondary progressive form of MS. Overall, the presence of these cells in the spinal fluid at diagnosis did not help predict who would do worse in the long run.

Who Should Care and Why

People with MS and their caregivers should know that finding extra white blood cells in the spinal fluid at diagnosis is not a sign that disability will be worse years later. This may ease anxiety if a lumbar puncture (spinal tap) shows mild inflammation, because it alone did not mean a worse future for most people in this study. Neurologists and MS nurses can use this information when explaining test results, focusing on other signs and tests instead of this one result alone. Patients starting or considering treatments can be reassured that this single test result is not a clear guide for long-term outcome, so treatment decisions should consider symptoms and MRI results too. Caregivers can think of this like a single weather reading: one cloudy measurement doesn’t predict the whole season—doctors need more information to forecast the future.

Important Considerations

This study was done in two centers in the English Midlands and most participants had the relapsing form of MS, so results might be different in other places or in other MS types. The spinal fluid test was a single snapshot in time; disease activity can change, so one test may miss later changes. Because medicine and treatments have changed over the years, the results may not fully apply to people diagnosed or treated under newer approaches.

AI-generated summary — for informational purposes only, not medical advice

Categories:

MS Progression MS Diagnostics Early Research

Article Topics:

Cerebrospinal fluidMultiple sclerosisPleocytosisPrognosis

Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like Journal of neurology often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.

However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.

By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.

Back to News